An Observational Study of Anaemia Management in Patients with NHL Receiving CHOP-14 or -21 (With or Without Rituximab)

Verhoef, Gregor; Erik Johnsen, Hans; Gaia Rossi, Francesca; Salar, Antonio; Hamilton, Lisa; Marieke Schoonen, W.; Pujol, B.; Dührsen, Ulrich

doi:10.1182/blood.v112.11.4948.4948

Public

An Observational Study of Anaemia Management in Patients with NHL Receiving CHOP-14 or -21 (With or Without Rituximab)

Published in Blood • Nov 16, 2008

Authors:

Gregor Verhoef

Hans Erik Johnsen

Francesca Gaia Rossi

Abstract

Abstract Background: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) therapy is standard treatment for aggressive Non-Hodgkin’s Lymphoma (NHL), and frequently results in myelosuppression. The resulting febrile neutropenia (FN) and chemotherapy-induced anaemia (CIA) may be treated with ...

Subject

Medicine

Rituximab

Vincristine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!